Long before, experts have considered psoriasis to be a long-lasting autoimmune disease primarily characterized by abnormal patches on skin. However, although symptoms and signs vary, doctors say that they notably include red, scaling plaques of itchy, elevated skin affecting the elbows, knees and scalp. In line with this condition, UCB and Dermira Inc. have recently announced that they have obtained positive results from a Phase 3 clinical trial assessing the safety and efficacy of its drug Cimzia or sometimes called umab pegol. Researchers claim that Cimzia has the ability to treat adult patients inflicted with moderate-to- severe chronic plaque psoriasis.
Cimzia And Its Features
According to reports revealed by Pharma Times, the data that has been gathered from the CIMPACT study has showed that the drug allegedly generated significant improvements in skin clearance as compared to the usual placebo. As researchers have explained, at week 12, the response rate for patients receiving Cimzia 400mg every two weeks and 61.3 percent for those getting Cimzia 200mg every two weeks have induced a 66.7 percent improvement. And at week 16, experts have noted that response rates from these patients were 74.7 percent and 68.2 percent, respectively as compared to those having a placebo.
UCB And Dermira Inc. On Psoriasis Cure
Furthermore, as per Investopedia, based from the series of recent successful results obtained from the Phase 3 trial, Dermira Inc., together with the Belgium-based UCB, are allegedly expecting to apply for the marketing authorization by the third quarter of 2017. The two firms have highly emphasized that throughout the course of these three CIMZIA Phase III clinical trials, the drug has reportedly demonstrated some statistically significant improvements for all primary or co-primary endpoints compared to placebo at both treatment doses. Ultimately, Emmanuel Caeymaex, head of Immunology and executive vice president, Immunology Patient Value Unit of UCB has claimed that the results taken from the research is a great support to their belief that Cimzia may one day be an important treatment option for patients living with psoriasis.
